Mindfulness-based cognitive therapy for Fear of Recurrence in Ovarian Cancer Survivors (FROCS): a single-arm, open-label, pilot study

• Published in: Supportive care in cancer Vol. 30; no. 3; pp. 2317 - 2325
• Main Authors: Cohen, Paul A., Musiello, Toni, Jeffares, Stephanie, Bennett, Kellie
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2022; Springer; Springer Nature B.V
• Subjects: Anxiety; Australia; Cancer; Cancer Survivors; Care and treatment; Clinical trials; Cognitive Behavioral Therapy; Cognitive therapy; Depression, Mental; Diseases; Fear; Fear & phobias; Female; Humans; Labels; Medicine; Medicine & Public Health; Mindfulness; Neoplasm Recurrence, Local; Nursing; Nursing Research; Oncology; Oncology, Experimental; Original Article; Ovarian cancer; Pain Medicine; Pilot Projects; Rehabilitation Medicine; Relapse; Survivor; Womens health; Australia; Supportive care; Mindfulness-based cognitive therapy; Fear of recurrence; Ovarian cancer
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-021-06659-y

Objective Fear of recurrence is common following treatment for cancer. Our aim was to assess the feasibility of mindfulness-based cognitive therapy (MBCT) to treat fear of cancer recurrence (FCR) in ovarian cancer survivors. Methods Investigator initiated, single-arm, open-label, pilot study. Women were eligible after completing adjuvant treatment. The intervention was an 8-week MBCT course of weekly 2-h group sessions. The primary outcome was FCR measured by the FCR inventory. Secondary outcomes were depression and anxiety measured by the Hospital Anxiety and Depression Scale (HADS). The study is registered with the Australian and New Zealand Clinical Trials Registry ACTRN12615000213549. Results Between May 8, 2015, and May 6, 2019, 33 participants were enrolled. Ten women withdrew. Data were evaluable for 19 participants. There was a significant decrease in FCR at 8 weeks (FCR inventory mean 63.00, SD 27.90) compared to pre-intervention (FCR inventory mean 71.03, SD 31.01) but not at 6 months (FCR inventory mean 63.65 , SD 30.08). No differences in depression were observed at baseline (HADS mean 3.42, SD 2.41), 8 weeks (HADS mean 3.10, SD 1.79) and 6 months (HADS mean 2.73, SD 1.88). Anxiety decreased from baseline (HADS mean 8.72, SD 3.99) at both 8 weeks (HADS mean 6.89, SD 2.98) and 6 months (HADS mean 7.06, SD 3.87). Conclusions MBCT may be effective as a treatment for FCR and anxiety in women following diagnosis and treatment of ovarian cancer. A randomised controlled trial is required to assess the efficacy of MBCT for FCR but may not be feasible due to high rates of withdrawal.